S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
China Threat Triggers Potential Mining Boom for Investors (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
China Threat Triggers Potential Mining Boom for Investors (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
China Threat Triggers Potential Mining Boom for Investors (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
China Threat Triggers Potential Mining Boom for Investors (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving

Cantor Fitzgerald Analysts Reduce Earnings Estimates for Sanara MedTech Inc. (NASDAQ:SMTI)

Sanara MedTech Inc. (NASDAQ:SMTI - Get Rating) - Equities research analysts at Cantor Fitzgerald lowered their FY2022 EPS estimates for Sanara MedTech in a report released on Tuesday, November 22nd. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($1.44) per share for the year, down from their previous forecast of ($1.31). The consensus estimate for Sanara MedTech's current full-year earnings is ($1.31) per share. Cantor Fitzgerald also issued estimates for Sanara MedTech's FY2023 earnings at ($0.38) EPS.

Sanara MedTech Stock Performance

Shares of SMTI opened at $36.48 on Thursday. The company's 50 day simple moving average is $30.94 and its 200-day simple moving average is $26.91. Sanara MedTech has a 12-month low of $17.41 and a 12-month high of $39.99.

Insider Transactions at Sanara MedTech

In other news, insider Shawn M. Bowman sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $27.89, for a total transaction of $27,890.00. Following the transaction, the insider now directly owns 18,550 shares in the company, valued at $517,359.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 2,000 shares of company stock worth $60,890. Insiders own 58.40% of the company's stock.

Hedge Funds Weigh In On Sanara MedTech


Hedge funds have recently modified their holdings of the business. State Street Corp grew its position in Sanara MedTech by 8.3% in the 1st quarter. State Street Corp now owns 8,013 shares of the company's stock valued at $222,000 after buying an additional 613 shares during the last quarter. Lazard Asset Management LLC grew its position in Sanara MedTech by 54.3% in the 2nd quarter. Lazard Asset Management LLC now owns 1,764 shares of the company's stock valued at $36,000 after buying an additional 621 shares during the last quarter. Citadel Advisors LLC purchased a new position in Sanara MedTech in the 2nd quarter valued at $229,000. First Manhattan Co. purchased a new position in Sanara MedTech in the 3rd quarter valued at $47,000. Finally, Quadrature Capital Ltd purchased a new position in Sanara MedTech in the 3rd quarter valued at $204,000. 3.15% of the stock is currently owned by hedge funds and other institutional investors.

About Sanara MedTech

(Get Rating)

Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Sanara MedTech right now?

Before you consider Sanara MedTech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanara MedTech wasn't on the list.

While Sanara MedTech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here